A476040 Stock Overview

Develops regenerative therapies in South Korea. More details

A476040 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue grew by 22.8% over the past year

Risk Analysis

Shares are highly illiquid

Does not have meaningful revenue (₩2B)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Organoidsciences Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Organoidsciences
Historical stock prices
Current Share Price	₩48,150.00
52 Week High	₩48,850.00
52 Week Low	₩23,000.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	50.47%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A476040	KR Pharmaceuticals	KR Market
7D	33.0%	-1.3%	-0.6%
1Y	n/a	-5.1%	-6.9%

Return vs Industry: Insufficient data to determine how A476040 performed against the KR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how A476040 performed against the KR Market.

Price Volatility

Is A476040's price volatile compared to industry and market?
A476040 volatility
A476040 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	6.2%
10% most volatile stocks in KR Market	12.5%
10% least volatile stocks in KR Market	3.0%

Stable Share Price: A476040's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A476040's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Jong-Man Yoo	organoidrx.com

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

Organoidsciences Ltd. Fundamentals Summary

How do Organoidsciences's earnings and revenue compare to its market cap?
A476040 fundamental statistics
Market cap	₩263.49b
Earnings (TTM)	-₩11.25b
Revenue (TTM)	₩1.95b

160.4x

P/S Ratio

-27.9x

P/E Ratio

Is A476040 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A476040 income statement (TTM)
Revenue	₩1.95b
Cost of Revenue	₩42.80m
Gross Profit	₩1.91b
Other Expenses	₩13.16b
Earnings	-₩11.25b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.73k
Gross Margin	97.81%
Net Profit Margin	-575.78%
Debt/Equity Ratio	37.3%

How did A476040 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/21 12:18
End of Day Share Price	2025/05/21 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Organoidsciences Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.